(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
29 October 2009 (29.10.2009)

PCT

(10) International Publication Number
WO 2009/130434 A1

(51) **International Patent Classification**:
C07D 333/38 (2006.01) *A61P 25/28* (2006.01)
A61K 31/381 (2006.01) *A61P 37/00* (2006.01)

(21) **International Application Number**:
PCT/GB2008/001434

(22) **International Filing Date**:
23 April 2008 (23.04.2008)

(25) **Filing Language**: English

(26) **Publication Language**: English

(71) **Applicant** *(for all designated States except US)*: **CHROMA THERAPEUTICS LTD.** [GB/GB]; 93 Milton Park, Abingdon, Oxfordshire OX14 4RY (GB).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **MOFFAT, David, Festus, Charles** [GB/GB]; Chroma Therapeutics Ltd., 93 Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). **DAVIES, Stephen, John** [GB/GB]; Chroma Therapeutics Ltd., 93 Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). **CHARLTON, Michael, Hugh** [GB/GB]; Chroma Therapeutics Ltd., 93 Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). **HIRST, Simon, Christopher** [GB/GB]; Sygnature Chemical Services Ltd., Biocity Nottingham, Pennyfoot Street, Nottingham NG1 1GF (GB). **ONIONS, Stuart, Thomas** [GB/GB]; Sygnature Chemical Services Ltd., Biocity Nottingham, Pennyfoot Street, Nottingham NG1 1GF (GB). **WILLIAMS, Jonathon, Gareth** [GB/GB]; Sygnature Chemical Services Ltd., Biocity Nottingham, Pennyfoot Street, Nottingham NG1 1GF (GB).

(74) **Agent**: **WALLS, Alan, James**; P.O. Box 223, Tadworth, Surrey KT20 5YF (GB).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

WO 2009/130434 A1

(54) **Title**: INHIBITORS OF IKK-β SERINE-THREONINE PROTEIN KINASE

(57) **Abstract**: Cyclopentyl (2S,4*E*)-2-amino-5-{3-[4-carbamoyl-5 (carbamoylamino)-2-thienyl]phenyl}pent-4-enoate; Cyclopentyl 5-{3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]phenyl}-L-norvalinate; Cyclopentyl (2S,4*E*)-2-amino-5-{3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]-5-methylphenyl}pent-4-enoate; Cyclopentyl (2S,4*E*)-2-amino-5-{5-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]-2-methylphenyl}pent-4-enoate; Cyclopentyl *O*-{3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]phenyl}-L-homoserinate; Cyclopentyl *O*-{3-[4-carbamoyl-5-(carbamoylamino)-2-thienylJphenyl}-L-homoserinate; Cyclopentyl *N*-{3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]benzyl}-L-alaninate; and *tert*-Butyl *N*-{3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]benzyl}-L-alaninate are hydrolysed to the corresponding carboxylic acids by intracellular carboxylesterases, and are useful for the inhibition of IKKβ activity.